发明名称 IMMEDIATE RELEASE 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide FORMULATION
摘要 A solid dosage form of nilotinib is disclosed that comprises: (i) a core comprising 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1 H-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide or a pharmaceutically acceptable salt thereof and excipients; and (ii) at least one polymer, said polymer coating said core, wherein disintegration of said solid dosage form is delayed
申请公布号 US2015320749(A1) 申请公布日期 2015.11.12
申请号 US201414273874 申请日期 2014.05.09
申请人 Bhardwaj Upkar;Comfort Ann Reese;Li Ping;Li Shoufeng;Makarov Alexey;Bordawekar Mangesh Sadashiv 发明人 Bhardwaj Upkar;Comfort Ann Reese;Li Ping;Li Shoufeng;Makarov Alexey;Bordawekar Mangesh Sadashiv
分类号 A61K31/506;A61K9/28 主分类号 A61K31/506
代理机构 代理人
主权项 1. A solid dosage form comprising: (i) a core comprising 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide or a pharmaceutically acceptable salt thereof and excipients; and (ii) at least one polymer, said polymer coats 7-13% of said core, wherein disintegration of said solid dosage form is delayed by 4-15 minutes.
地址 Coram NY US